Pulmonary disease in systemic lupus erythematosus

Area of Science:

• Rheumatology
• Pulmonology
• Internal Medicine

Background:

• Pulmonary involvement is a frequent manifestation of systemic lupus erythematosus (SLE).
• SLE-related lung disease presents a wide spectrum of clinical conditions, from mild pleuritic pain to life-threatening pulmonary hemorrhage.
• Pulmonary manifestations can be the initial sign of this multisystem autoimmune disease.

Purpose of the Study:

• To outline the diverse pulmonary manifestations of SLE.
• To discuss the tailored treatment strategies for various lupus-related lung conditions.
• To emphasize the importance of excluding infection before attributing pulmonary findings to SLE.

Main Methods:

• Review of clinical spectrum and treatment options for pulmonary manifestations in SLE.
• Discussion of pharmacologic interventions including NSAIDs, corticosteroids, and immunosuppressants.
• Consideration of combination therapies and supportive care for severe cases.

Main Results:

• Treatment for SLE pulmonary disease is individualized based on clinical presentation.
• Non-steroidal anti-inflammatory drugs (NSAIDs) may suffice for pleuritic pain.
• High-dose corticosteroids are indicated for more severe conditions like lupus pneumonitis and interstitial lung disease.
• Immunosuppressants (azathioprine, cyclophosphamide) are considered for steroid-refractory cases.
• Combined therapies (corticosteroids, immunosuppressants, plasmapheresis) may be used for diffuse pulmonary hemorrhage.
• No definitive treatment currently exists for pulmonary hypertension in SLE.
• Clinical evidence supporting specific therapies is limited.

Conclusions:

• Treatment for pulmonary manifestations of SLE requires individualized approaches.
• Aggressive immunosuppression may be necessary for severe lung disease unresponsive to initial therapies.
• Pulmonary hypertension in SLE lacks a defined treatment protocol.
• Exclusion of infectious causes is critical before diagnosing SLE-related pulmonary disease.